A comprehensive narrative of different signaling mechanisms of NRP1 in different diseases and how this cell surface receptor can be utilized in various therapeutic approaches to combat these diseases is provided.
Abstract
Neuropilin-1 (NRP1) is a developmentally conserved cell surface receptor that functionally acts to bind various ligands like class 3 semaphorins and several members of the VEGF family to engage in different signaling pathways that control cell migration and motility. Due to its widespread expression, NRP1 is implicated in immune function, axonal guidance, viral entry, tumor progression and angiogenesis. NRP1 is dysregulated across multiple cancer types and promotes tumor progression in a context-dependent manner in tumor cells and the tumor microenvironment, including endothelial, stromal, and immune-cell compartments. NRP1 is also involved in different autoimmune disorders, anosmia, and cardiovascular disorders. Phage display studies revealed that peptides containing C-terminal CendR motifs engage NRP1 for tissue penetration. Apart from cell-penetrating peptides, monoclonal antibodies against NRP1 also present a promising target for cancer therapeutics. Importantly, NRP1 in SARS-CoV-2 infection act as an auxiliary host factor, and furin cleavage of the viral spike protein exposes a C-terminal CendR motif that can bind NRP1, thereby facilitating viral entry. However, NRP1 is not an independent receptor comparable to ACE2, thus, NRP1-targeted antiviral strategies need further investigations. Given the above, the review provides comprehensive narrative of different signaling mechanisms of NRP1 in different diseases and how this cell surface receptor can be utilized in various therapeutic approaches to combat these diseases.
Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein involved in cardiovascular protection, tissue repair, inflammation, fibrosis, and tumor biology. Accumulating evidence indicates that FSTL1 exerts opposing effects across tissues and disease contexts, producing either protective or pathogenic outcomes. Altho...
Yu Hou, C. Fang, Wen-Qi Yang et al.· Biochemical Pharmacology· 0 citations
The discoidin domain receptor 1 (DDR1) is a collagen-activated receptor tyrosine kinase that orchestrates multiple cellular processes and remodels the tumor immune microenvironment (TIME). Notably, DDR1 promotes immune exclusion predominantly through its extracellular domain, which regulates collagen fiber alignment to...
Xiao-Xiao Xu, Zhen-Xing Wang· Frontiers in Immunology· 0 citations
Highlights What are the main findings? NRG1 emerges as a context-dependent regulator of neuroinflammation that coordinates microglial, astrocytic, oligodendroglial, neuronal, and neurovascular responses through ErbB receptor signaling rather than functioning as a uniformly anti-inflammatory molecule. Across multiple pr...
Gregory D. Ford, Christopher McGinley, Oluwafayokemi Oyolola et al.· Cells· 0 citations
Its complex interactome, which includes cytoskeletal regulators, molecular chaperones, nuclear transport proteins, and cell surface receptors, positioning S100A6 as a central signaling hub, is detailed.
Jing Zhang, Peng Tang, Linshu Huang et al.· Frontiers in Pharmacology· 0 citations
Orphan nuclear receptor 4A1 (NR4A1) and NR4A2 exhibit pro-oncogenic activities in most solid tumors, and this study investigates the role of both receptors and the dual NR4A1/2 1,2-bis(3’-indolyl)-1-(3,5-disubstitutedphenyl)methane (DIM-3,5) ligands as inducers of ferroptosis in colon cancer cells. DIM-3,5 ligands...
A. R. Oany, Srijana Upadhyay, Gus A. Wright et al.· Cell Death Discovery· 0 citations
Butyrophilin-like 2 (BTNL2) is a Type I transmembrane glycoprotein of the immunoglobulin superfamily (IgSF) that functions as a tissue-specific immune checkpoint regulator with structural homology to B7 ligands. BTNL2 suppresses T cell activation by attenuating IL-2 secretion through the AP-1, NFAT, and NF-κB pathways....
Ishwar Patidar, Ramya Aswthareddy, A. Lakshminarasimhan et al.· Journal of Molecular Recogni...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.